Köstering H, Bandura B, Merten H A, Wieding J U
Arzneimittelforschung. 1985;35(8):1303-6.
The analyses on hemostaseological variables are recorded in connection with blood tests in the course of a double-blind study in 41 patients suffering from chronic venous insufficiency of higher degrees of severity. They were treated in addition to compression measures with two active ingredients, a coumarin (5,6-benzo-alpha-pyrone)/troxerutin combination (Venalot Depot) (n = 20) or benzarone (n = 21) receiving 3 X 2 dragees daily for 6 weeks. Good clinical efficacy and the improvement of symptoms were observed together with almost no side-effects. The coagulation analysis showed no influence of the active principles on the global coagulation or the clotting factors and the inhibitors and factors of the fibrinolysis. In particular there was no phenprocoumon-like effect on the blood clotting system.
在一项针对41例重度慢性静脉功能不全患者的双盲研究过程中,对止血学变量的分析与血液检测相关联进行记录。除了采用压迫措施外,他们还接受两种活性成分治疗,一种是香豆素(5,6-苯并-α-吡喃酮)/曲克芦丁组合(维脉宁长效制剂)(n = 20),另一种是苄酮香豆素(n = 21),每日服用3次,每次2片,持续6周。观察到良好的临床疗效和症状改善,且几乎没有副作用。凝血分析表明,这些活性成分对整体凝血、凝血因子以及纤维蛋白溶解的抑制剂和因子均无影响。特别是对血液凝固系统没有苯丙香豆素样的作用。